- Research works
- 21 ▼ 67% vs 2013–17
- Citations
- 918 43.0 per fractional work
- Top-10% rate
- 0.0% record average 16.5%
- Open access
- 55% world 28%
Not ranked overall: VasGene Therapeutics (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Which keywords describe research at VasGene Therapeutics (United States)?
By fractional works in all years, weighted toward what it does more of than the world: Cell Signaling, Receptor tyrosine kinases, Eph receptors, Semaphorins, Cancer, Cancer Immunotherapy, endothelial progenitor cells and VEGF.
- Tumor Microenvironment
- Dendritic Cells
- Regulation
- Hippo Pathway
- Cell Proliferation
- endothelial progenitor cells
- Stem Cells
- Cancer Immunotherapy
- Semaphorins
- Receptor tyrosine kinases
- Cell Signaling
- Eph receptors
- Cancer
- Cancer Therapy
- VEGF
- Immunotherapy
- Antigen Presentation
- Innate Immunity
- YAP/TAZ
- Immunity
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 20 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 20 words, with their numbers
- Cell Signaling4▲ 56×2 topics
- Receptor tyrosine kinases4▲ 368×2 topics
- Eph receptors3▲ 1123×1 topic
- Semaphorins3▲ 1123×1 topic
- Cancer2▲ 8.3×10 topics
- Cancer Immunotherapy2▲ 56×3 topics
- Cancer Therapy2▲ 12×5 topics
- Stem Cells2▲ 26×4 topics
- VEGF2▲ 222×1 topic
- endothelial progenitor cells2▲ 222×1 topic
- Immunotherapy1▲ 10.0×7 topics
- Cell Proliferation1▲ 68×2 topics
- Antigen Presentation1▲ 57×2 topics
- Hippo Pathway1▲ 447×1 topic
- Innate Immunity1▲ 16×2 topics
- Regulation1▲ 9.5×2 topics
- YAP/TAZ1▲ 447×1 topic
- Dendritic Cells1▲ 43×1 topic
- Immunity1▲ 15×1 topic
- Tumor Microenvironment1▲ 14×3 topics
Which research topics does VasGene Therapeutics (United States) publish most on?
By volume in 2022–2025: Drug Transport and Resistance Mechanisms, Cancer therapeutics and mechanisms, Nanoplatforms for cancer theranostics and Peptidase Inhibition and Analysis.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Drug Transport and Resistance Mechanisms Oncology 0 works
- 2 Cancer therapeutics and mechanisms Molecular Biology 0 works
- 3 Nanoplatforms for cancer theranostics Biomedical Engineering 0 works
- 4 Peptidase Inhibition and Analysis Oncology 0 works
- 5 Cancer-related gene regulation Molecular Biology 0 works
- 6 Fibroblast Growth Factor Research Molecular Biology 0 works
- 7 Ubiquitin and proteasome pathways Molecular Biology 0 works
- 8 14-3-3 protein interactions Molecular Biology 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has VasGene Therapeutics (United States)'s research output changed?
Output in 2018–2022 was 67% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Los Angeles
- University of California, Los Angeles
- University of Southern California
- Cedars-Sinai Medical Center
- Film Independent
- UCLA Health
- Children's Hospital of Los Angeles
- California State University Los Angeles
- Loyola Marymount University
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.